A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers
Phase 1
Terminated
- Conditions
- Chronic Hepatitis C
- Registration Number
- NCT00522808
- Lead Sponsor
- Arrow Therapeutics
- Brief Summary
The purposes of this study are:
* to determine the safety and tolerability of multiple doses of A-831 at various doses
* to determine how multiple doses of A-831 are distributed through the bloodstream
* to determine if A-831 reduces the amount of Hepatitis C virus in the blood
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Male
- Target Recruitment
- 36
Inclusion Criteria
- Volunteers will be males of any race aged 18-60 years with a BMI between 18 and 32 kg/m2 at the time of the screening medical
- Volunteers who have given their written informed consent to participate in the study
- Volunteers who are willing and able to comply with the protocol and study procedures
- Volunteers who have a diagnosis of chronic hepatitis C infection and are in good health (other than history of Hepatitis C infection)
Exclusion Criteria
- Voulnteers with concurrent medical conditions or taking concurrent medications
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Antiviral activity Safety PK Tolerability
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
ACS
🇳🇿Auckland, New Zealand
Birmingham WTCRF
🇬🇧Birmingham, United Kingdom
DDS
🇬🇧Dundee, United Kingdom